EXHIBIT 10.1 CONFIDENTIAL TREATMENT REQUESTED - REDACTED COPY CONFIDENTIAL TREATMENT REQUESTED: INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND NOTED WITH "***." AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN SUBMITTED...Development and Supply Agreement • March 30th, 2005 • Halozyme Therapeutics Inc • Biological products, (no disgnostic substances) • California
First amendment to development and supply agreement for BA058 microneedle patchDevelopment and Supply Agreement • February 12th, 2021
Pursuant to Paragraph 9.4 of the Agreement, the parties wish to enter into this Amendment No. 1 to the Agreement (“Amendment No. 1”) effective as of December 31, 2009 (“Amendment Date”). Capitalized terms used in this Amendment No. 1 and not defined herein are used with the meanings ascribed to them in the Agreement.
ContractDevelopment and Supply Agreement • September 26th, 2016 • ViewRay, Inc. • Electromedical & electrotherapeutic apparatus
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
DEVELOPMENT AND SUPPLY AGREEMENTDevelopment and Supply Agreement • September 26th, 2016 • ViewRay, Inc. • Electromedical & electrotherapeutic apparatus • Ohio
This Development and Supply Agreement (“Agreement”) is entered into as of June 1, 2010 (“Effective Date”) by and between ViewRay Incorporated, a Delaware corporation (“ViewRay”), and Quality Electrodynamics, LLC, a Ohio limited liability company (“QED”).
PEKO 7/21/10 DEVELOPMENT AND SUPPLY AGREEMENTDevelopment and Supply Agreement • September 26th, 2016 • ViewRay, Inc. • Electromedical & electrotherapeutic apparatus • New York
This Development and Supply Agreement (“Agreement”) is entered into as of July 2, 2010 (“Effective Date”) by and between ViewRay Incorporated, a Delaware corporation (“ViewRay”), and PEKO Precision Products, Inc., a New York corporation (“PEKO”).
AMENDMENT TO DEVELOPMENT AND SUPPLY AGREEMENTDevelopment and Supply Agreement • September 26th, 2016 • ViewRay, Inc. • Electromedical & electrotherapeutic apparatus
This Amendment to Development and Supply Agreement (“Amendment”), dated as of January 20, 2015 (“Amendment Effective Date”) and is entered into by and between ViewRay, Inc., a Delaware corporation with its principal offices at 2 Thermo Fisher Way, Oakwood Village, OH 44146 (“ViewRay”) and Tesla Engineering Limited, a company organized under the laws of England and whose registered office is at Water Lane Industrial Estate, Storrington, West Sussex RH20 3EA (“Tesla”).
DEVELOPMENT AND SUPPLY AGREEMENTDevelopment and Supply Agreement • September 26th, 2016 • ViewRay, Inc. • Electromedical & electrotherapeutic apparatus • Delaware
This Development and Supply Agreement (“Agreement”) is entered into as of July 9, 2009 (“Effective Date”) by and between ViewRay Incorporated, a Delaware corporation with file number 4450114 and whose principal place of business is #2 Thermo Fisher Way, Oakwood Village, Ohio 44146, USA (“ViewRay”), and Tesla Engineering Limited, a company organized under the laws of England with registered company number 02786571 and whose registered office is at Water Lane Industrial Estate, Storrington, West Sussex RH20 3EA (“Tesla”).
DEVELOPMENT AND SUPPLY AGREEMENTDevelopment and Supply Agreement • September 26th, 2016 • ViewRay, Inc. • Electromedical & electrotherapeutic apparatus • New York
This Development and Supply Agreement (“Agreement”) is entered into as of June 24, 2009 (“Effective Date”) by and between ViewRay Incorporated, a Delaware corporation (“ViewRay”), Manufacturing Sciences Corporation (hereinafter “MSC”) a Colorado corporation.
ContractDevelopment and Supply Agreement • September 26th, 2016 • ViewRay, Inc. • Electromedical & electrotherapeutic apparatus
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
Confidential Treatment has been requested as to certain portions of this document. Each such portion, which has been omitted herein and replaced with an asterisk [*], has been filed separately with the Securities and Exchange Commission.] CONFIDENTIAL...Development and Supply Agreement • May 5th, 2020 • New York
This Development and Supply Agreement (this “Agreement”), effective as of November 26, 2018 (the “Effective Date”) is entered into by and between Qorvo Biotechnologies, LLC having its principal place of business at 14505 21st Ave. N., Suite 212, Plymouth, MN 55447, USA (“Qorvo”), and Zomedica Pharmaceuticals Corp., having its principal place of business at 100 Phoenix Drive, Suite 190, Ann Arbor, MI 48108 (“Zomedica”). Each of Qorvo and Zomedica may hereafter be referred to as a “Party” or collectively as the “Parties.”
EXHIBIT 10.8 TODevelopment and Supply Agreement • July 16th, 1999 • Watchguard Technologies Inc • Services-prepackaged software • California
ContractDevelopment and Supply Agreement • September 26th, 2016 • ViewRay, Inc. • Electromedical & electrotherapeutic apparatus
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
DEVELOPMENT AND SUPPLY AGREEMENTDevelopment and Supply Agreement • April 5th, 2019 • TransMedics Group, Inc. • Electromedical & electrotherapeutic apparatus • England and Wales
THIS AGREEMENT is made this 24th day of May 2005, (the “Effective Date”) by and between FRESENIUS KABI AB, a company formed under the laws of Sweden (“FRESENIUS”) and TransMedics Inc., a corporation formed under the laws of Delaware, USA (“TRANSMEDICS”). Each of FRESENIUS and TRANSMEDICS are a “Party”, and together they are the “Parties”. References to FRESENIUS and TRANSMEDICS, or collectively to the Parties, shall include their respective Affiliates.
CERTAIN INFORMATION (INDICATED BY “[***]”) IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.Development and Supply Agreement • April 1st, 2011 • Netlist Inc • Semiconductors & related devices • California
This Development and Supply Agreement (“Agreement”) is made this 10th day of September 2008 (“Effective Date”) between Diablo Technologies, Inc,, a Canadian corporation having a principal place of business at 290 St. Joseph, Suite 200, Gatineau, Quebec J8Y 3Y3 (“Diablo”) and Netlist, Inc., a Delaware corporation having a principal place of business at 51 Discovery, Irvine, CA 92618 (“Netlist”).
DEVELOPMENT AND SUPPLY AGREEMENTDevelopment and Supply Agreement • October 20th, 2006 • Thermage Inc • Electromedical & electrotherapeutic apparatus • California
This DEVELOPMENT AND SUPPLY AGREEMENT (“Agreement”), effective as of October 1, 1997, (the “Effective Date”), by and between Thermage, a California corporation, having a principal place of business at 905 San Ramon Valley Blvd., #110, Danville, California 94526 (“Thermage”), and Stellartech Research Corporation, having a principal place of business at 2665 Marine Way, Mountain View, California 94043 (“Stellartech”).
ContractDevelopment and Supply Agreement • September 26th, 2016 • ViewRay, Inc. • Electromedical & electrotherapeutic apparatus
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
DEVELOPMENT AND SUPPLY AGREEMENT BETWEEN V.I. TECHNOLOGIES, INC. AND HAEMONETICS CORPORATIONDevelopment and Supply Agreement • November 13th, 2001 • V I Technologies Inc • Biological products, (no disgnostic substances) • Massachusetts
JUNE 14, 2000Development and Supply Agreement • July 27th, 2000 • Microtune Inc • Semiconductors & related devices • California
WITNESSETH:Development and Supply Agreement • August 6th, 1997 • Computer Motion Inc • Electromedical & electrotherapeutic apparatus • California
CONFIDENTIAL DEVELOPMENT AND SUPPLY AGREEMENTDevelopment and Supply Agreement • May 8th, 2017 • Immuron LTD • Pharmaceutical preparations • Victoria
Immuron Ltd,. an Australian corporation having its principal place of business located at 39 Leveson Street, North Melbourne. Victoria 3051, Australia (Immuron); and
EX-10.39 3 dex1039.htm DEVELOPMENT AND SUPPLY AGREEMENT WITH ABBOTT LABORATORIES ZYMOGENETICS, INC. DEVELOPMENT AND SUPPLY AGREEMENTDevelopment and Supply Agreement • May 5th, 2020 • New York
This Agreement is entered into this 1st day of October, 2003 (“Effective Date”) by and between Abbott Laboratories, an Illinois corporation having a principal place of business at 100 Abbott Park Road, Abbott Park, Illinois 60064-3500 (“Abbott”), and ZymoGenetics, Inc. having a principal place of business at 1201 Eastlake Avenue East in Seattle WA, 98102 (“ZymoGenetics”).
BACKGROUNDDevelopment and Supply Agreement • March 29th, 2000 • Luminex Corp • Services-commercial physical & biological research • California
ContractDevelopment and Supply Agreement • August 8th, 2008 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances)
Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as [***]. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.
ContractDevelopment and Supply Agreement • September 26th, 2016 • ViewRay, Inc. • Electromedical & electrotherapeutic apparatus
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
DEVELOPMENT AND SUPPLY AGREEMENTDevelopment and Supply Agreement • September 5th, 2014 • Endostim, Inc. • Electromedical & electrotherapeutic apparatus • New York
THIS DEVELOPMENT AND SUPPLY AGREEMENT (the “Agreement”) is made and entered into this March 31, 2013 (the “Execution Date”) between EndoStim, Inc., with its principal business address in St. Louis, MO, USA (“EndoStim”), and C.C.C. DEL URUGUAY S.A., a Uruguayan corporation with its principal business address in Montevideo, Uruguay (“CCC”).
DEVELOPMENT AND SUPPLY AGREEMENT by and between GLAND PHARMA LIMITED, an Indian corporation and SAGENT HOLDING CO., a Cayman Islands corporation for Heparin Sodium Injection USP Dated: June 27, 2008Development and Supply Agreement • February 2nd, 2011 • Sagent Holding Co. • Pharmaceutical preparations • New York
THIS DEVELOPMENT AND SUPPLY AGREEMENT (“Agreement”) is made as of the 27th day of June, 2008 (the “Effective Date”) by and between GLAND PHARMA LIMITED, an Indian corporation, having a place of business at 6-3-865/1/2, Ameerpet, Hyderabad, India (“Gland”), and SAGENT HOLDING CO., a Cayman Islands corporation, having a place of business at c/o M&C Corporate Services Limited, PO Box 309 GT, Ugland House, South Church Street, George Town, Grand Cayman, Cayman Islands (“Sagent”).
DEVELOPMENT AND SUPPLY AGREEMENTDevelopment and Supply Agreement • February 17th, 2004 • Xcyte Therapies Inc • Pharmaceutical preparations
This Development and Supply Agreement (the “Agreement”) is made and entered into as of the 1st day of August, 1999 (the “Effective Date”) by and between XCYTE THERAPIES, INC., a Delaware corporation with offices at 1124 Columbia Street. Suite 130 Seattle, Washington 98104 (hereinafter referred to as “Xcyte”), and DYNAL A.S., a Norwegian corporation, with offices at P.O. Box 158, Skøyen, N-0212 Oslo, Norway (hereinafter referred to as “Dynal”).
OraSure, Thermo Fisher agreement, 2/14Development and Supply Agreement • September 2nd, 2021
February 2014—OraSure Technologies has reached an agreement with Thermo Fisher Scientific to develop and supply up to 12 homogenous, fully automated oral fluid drugs-of-abuse assays to be used with OraSure’s new Intercept oral fluid specimen collection device. OraSure will have the right to purchase and resell the assays in the U.S. and certain foreign countries, subject to receipt of applicable regulatory approvals.
REDACTED COPY DEVELOPMENT AND SUPPLY AGREEMENTDevelopment and Supply Agreement • October 20th, 2023 • Inno Holdings Inc. • Steel pipe & tubes • Texas
THIS DEVELOPMENT AND SUPPLY AGREEMENT (the “Agreement”) is entered into as of March 24, 2023 by and between Vision Opportunity Fund LP (“Client”) having an address at 50210 Bermont Rd, Punta Gorda, FL 33982 and Inno Metal Studs Corp (“Inno”) having an address at 2465 FM-359 S, Brookshire TX 77423.
WITNESSETH:Development and Supply Agreement • June 1st, 2001 • Macropore Inc • Orthopedic, prosthetic & surgical appliances & supplies • Minnesota
DEVELOPMENT AND SUPPLY AGREEMENTDevelopment and Supply Agreement • November 8th, 2013 • Cempra, Inc. • Pharmaceutical preparations • Delaware
THIS DEVELOPMENT AND SUPPLY AGREEMENT (the “Agreement”) is entered into and made effective as of July 1, 2013 (the “Effective Date”), by and between CEMPRA PHARMACEUTICALS, INC., a Delaware corporation (“Cempra”) and HOSPIRA WORLDWIDE, INC., a Delaware corporation (“Hospira”).
DEVELOPMENT AND SUPPLY AGREEMENT between LONZA SALES AG and MICROMET AGDevelopment and Supply Agreement • July 20th, 2010 • Micromet, Inc. • Biological products, (no disgnostic substances)
*** Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
Development and Supply AgreementDevelopment and Supply Agreement • July 27th, 2023 • Monogram Orthopaedics Inc • Surgical & medical instruments & apparatus • California
This Development and Supply Agreement (this “Agreement”) entered into by and between Pro-Dex, Inc., a Colorado corporation (“Pro-Dex”), and Monogram Orthopaedics Inc., a Delaware corporation (“Monogram,” and together with Pro-Dex, the “Parties”), shall be effective if and when, and only if and when, the Effectiveness Conditions (as defined in Section 14 below) have been satisfied.
EXHIBIT 10.18 [LOGO OF GENERAL INSTRUMENT/(R)/ APPEARS HERE] C 0 N F I D E N T I A L ----------------------- DEVELOPMENT AND SUPPLY AGREEMENT by and between MICROTUNE, INC.Development and Supply Agreement • August 3rd, 2000 • Microtune Inc • Semiconductors & related devices • California
FORDevelopment and Supply Agreement • August 14th, 2001 • Bei Technologies Inc • Industrial instruments for measurement, display, and control • Michigan
